Superior survival benefits of triple combination immunotherapy compared to standard chemotherapy as second-line treatment for advanced biliary tract cancer: a retrospective analysis DOI Creative Commons
Peipei Shang,

Heming Xu,

Tianmei Zeng

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Nov. 22, 2024

Advanced biliary tract cancer (BTC) is associated with a poor prognosis and limited options for second-line treatment. The TOPAZ-1 KEYNOTE-966 trials have demonstrated the benefits of combining immune checkpoint inhibitors (ICIs) chemotherapy in treating BTC. However, efficacy FOLFOX as therapy limited, highlighting need more effective treatment approaches.

Language: Английский

Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery DOI Creative Commons
Junyu Wu, Guping Tang, Chien‐shan Cheng

et al.

Molecular Cancer, Journal Year: 2024, Volume and Issue: 23(1)

Published: Oct. 1, 2024

Language: Английский

Citations

13
Biliary tract cancer DOI Creative Commons
Kjetil Søreide, Cristina Dopazo, Frederik Berrevoet

et al.

European Journal of Surgical Oncology, Journal Year: 2024, Volume and Issue: unknown, P. 108489 - 108489

Published: June 1, 2024

Biliary tract cancers comprise a heterogeneous collection of malignancies usually described as cholangiocarcinoma the intra- or extrahepatic bile duct, including perihilar and gallbladder cancer.

Language: Английский

Citations

6
The Recent Trends of Systemic Treatments and Locoregional Therapies for Cholangiocarcinoma DOI Creative Commons
Abdullah Esmail, Mohamed Badheeb,

Batool Wael Alnahar

et al.

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(7), P. 910 - 910

Published: July 8, 2024

Cholangiocarcinoma (CCA) is a hepatic malignancy that has rapidly increasing incidence. CCA anatomically classified into intrahepatic (iCCA) and extrahepatic (eCCA), which further divided perihilar (pCCA) distal (dCCA) subtypes, with higher incidence rates in Asia. Despite its rarity, low 5-year survival rate remains the leading cause of primary liver tumor-related death over past 10–20 years. The systemic therapy section discusses gemcitabine-based regimens as treatments, along oxaliplatin-based options. Second-line limited but may include short-term infusional fluorouracil (FU) plus leucovorin (LV) oxaliplatin. adjuvant approaches to improve overall (OS) post-surgery. However, only minority patients qualify for surgical resection. In comparison therapies, neoadjuvant unresectable cases shows promise. Gemcitabine cisplatin indicate potential benefits awaiting transplantation. addition immunotherapies chemotherapy combination discussed. Nivolumab innovative like CAR-T cells, TRBAs, oncolytic viruses are explored. We aim this review provide comprehensive report on locoregional therapies CCA.

Language: Английский

Citations

4
Efficacy and safety of arterial FOLFOX chemotherapy plus anti-PD-(L)1 immunotherapy as a first-line treatment for unresectable intrahepatic cholangiocarcinoma: a propensity score matching analysis DOI Open Access
Yue Hu, Xiongying Jiang,

Xi Cai

et al.

Journal of Gastrointestinal Oncology, Journal Year: 2025, Volume and Issue: 16(1), P. 209 - 225

Published: Feb. 1, 2025

Given the limited efficacy of current first-line therapies, there is an urgent need to develop novel treatment strategies improve prognosis patients with unresectable intrahepatic cholangiocarcinoma (uICC). This study aimed evaluate and safety hepatic arterial infusion chemotherapy (HAIC) infusional fluorouracil, leucovorin, oxaliplatin (FOLFOX) regimens (HAIC-FO) plus anti-programmed death-(ligand) 1 immunotherapy [αPD-(L)1] antibody [HAIC+αPD-(L)1] compared systemic (SYS) αPD-(L)1 [SYS+αPD-(L)1] as a for uICC. In this retrospective study, treatment-naive uICC who were treated HAIC+αPD-(L)1 or SYS+αPD-(L)1 included. The clinical characteristics, therapeutic outcomes, adverse events (AEs) in two groups compared. Propensity score matching (PSM) was performed minimize biases between groups. From January 2019 2023, total 182 enrolled; 147 included group 35 group. After PSM, 61 26 groups, respectively. had longer median overall survival (mOS), progression-free (mPFS), PFS (mIPFS) than did (mOS: 14.5 vs. 10.5 months, P=0.02; mPFS: 10.4 6.4 mIPFS: 11.4 6.5 P<0.001). incidence AEs comparable but lower grade 3-4 related anemia, leukopenia, weight loss, fatigue. acceptable toxic effects might outcomes

Language: Английский

Citations

0
IDHIRA: a prospective, observational study on ivosidenib in patients with IDH1 R132-mutated advanced cholangiocarcinoma DOI Creative Commons
Marlies Michl, Nora Hagemeyer,

M. Looß

et al.

Future Oncology, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 8

Published: March 3, 2025

Cholangiocarcinoma (CCA) is a rare and aggressive cancer with poor prognosis. Ivosidenib, an orally administered, first-in-class small-molecule inhibitor, targets the mutated isocitrate dehydrogenase 1 (IDH1) enzyme. Recently, ivosidenib has been approved for treating patients locally advanced or metastatic IDH1 R132-mutated CCA following at least one prior systemic therapy. The pivotal phase 3 ClarIDHy trial revealed that nearly doubled median progression-free survival significantly improved overall after adjusting crossover. However, prospective real-world data on remain limited. IDHIRA study prospective, multicenter, longitudinal, non-interventional conducted in Germany. will enroll 100 CCA, aiming to evaluate effectiveness, safety, quality of life (QoL) associated treatment patients.

Language: Английский

Citations

0
Genomic landscape of biliary tract cancer and corresponding targeted treatment strategies DOI Creative Commons
Daisaku Yamada, Shogo Kobayashi,

Yuichiro Doki

et al.

International Journal of Clinical Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: April 25, 2025

Abstract Biliary tract cancers (BTCs) are classified on the basis of their anatomical origin, and feasibility surgical resection depends tumor location extent progression. However, for unresectable BTCs, systemic therapy has been uniformly applied. Gemcitabine cisplatin (GC) GC-based therapies were established as first-line standard BTC treatment. no highly effective second-line established, prognosis remains poor, highlighting need further therapeutic advancements. Meanwhile, era precision medicine expanded use genetic testing, leading to identification actionable molecular targets in BTC. Several targeted therapies, including FGFR inhibitors IDH1 inhibitors, have developed, offering new treatment options potential appropriate cases. Notably, frequency these alterations varies depending location, demonstrating heterogeneity Therefore, it recognized that a tailored approach each patient may be more than uniform therapy. Consequently, although routine testing before initiating is currently limited by medical environment (e.g., cost, accessibility, regional differences), recommended ESMO guideline might increasingly advocated. harbors wide range alterations, numerous being developed accordingly. This review provides an overview reported BTC, frequencies corresponding emphasizing evolving role

Language: Английский

Citations

0
SENP3 induced HADHA deSUMOylation enhances intrahepatic cholangiocarcinoma chemotherapy sensitivity via fatty acid oxidation DOI

Jijun Shan,

Zhiwen Chen, Mo Chen

et al.

Cancer Letters, Journal Year: 2025, Volume and Issue: unknown, P. 217770 - 217770

Published: May 1, 2025

Language: Английский

Citations

0
Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study DOI Creative Commons
Do‐Youn Oh, Aiwu Ruth He, Shukui Qin

et al.

Journal of Hepatology, Journal Year: 2025, Volume and Issue: unknown

Published: May 1, 2025

Language: Английский

Citations

0
Identification of PANoptosis-relevant subgroups and predicting signature to evaluate the prognosis and immune landscape of patients with biliary tract cancer DOI Creative Commons
Dongming Liu, Wenshuai Chen, Zhiqiang Han

et al.

Hepatology International, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 10, 2024

This study conducted molecular subtyping of biliary tract cancer patients based on 19 PANoptosis-related gene signatures.

Language: Английский

Citations

3
Superior survival benefits of triple combination immunotherapy compared to standard chemotherapy as second-line treatment for advanced biliary tract cancer: a retrospective analysis DOI Creative Commons
Peipei Shang,

Heming Xu,

Tianmei Zeng

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Nov. 22, 2024

Advanced biliary tract cancer (BTC) is associated with a poor prognosis and limited options for second-line treatment. The TOPAZ-1 KEYNOTE-966 trials have demonstrated the benefits of combining immune checkpoint inhibitors (ICIs) chemotherapy in treating BTC. However, efficacy FOLFOX as therapy limited, highlighting need more effective treatment approaches.

Language: Английский

Citations

0